Skip to content

Study · Randomized controlled trial · n = 737 · 2013

8 results

Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.

Malloy J, Meloni A, Han J

Postgraduate medicine1 May 2013Cited by 6 (Europe PMC)

PMID23748507 (opens in a new tab)DOI10.3810/pgm.2013.05.2661 (opens in a new tab)PepBankPUB-23748507
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, weekly exenatide reduced HbA1c more than sitagliptin across all baseline HbA1c strata.

    In plain wordsIn patients with diabetes, weekly exenatide reduced HbA1c more than sitagliptin across starting HbA1c groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c across baseline strata
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    While both agents reduced HbA1c and fasting blood glucose (FBG) levels from baseline, significantly greater reductions in HbA1c and FBG levels occurred with EQW compared with sita across all baseline HbA1c level strata, and significantly more patients in the EQW group achieved goal HbA1c levels comp…
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, weekly exenatide reduced fasting glucose more than sitagliptin across all baseline HbA1c strata.

    In plain wordsIn patients with diabetes, weekly exenatide reduced fasting glucose more than sitagliptin across starting HbA1c groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting blood glucose across baseline strata
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    While both agents reduced HbA1c and fasting blood glucose (FBG) levels from baseline, significantly greater reductions in HbA1c and FBG levels occurred with EQW compared with sita across all baseline HbA1c level strata, and significantly more patients in the EQW group achieved goal HbA1c levels comp…
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, more weekly exenatide patients achieved goal HbA1c than sitagliptin patients.

    In plain wordsIn patients with diabetes, more patients reached the HbA1c goal with weekly exenatide than sitagliptin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c goal attainment
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    While both agents reduced HbA1c and fasting blood glucose (FBG) levels from baseline, significantly greater reductions in HbA1c and FBG levels occurred with EQW compared with sita across all baseline HbA1c level strata, and significantly more patients in the EQW group achieved goal HbA1c levels comp…
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, weekly exenatide reduced body weight more than sitagliptin.

    In plain wordsIn patients with diabetes, weekly exenatide reduced weight more than sitagliptin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with EQW also experienced significantly greater reductions in body weight and cholesterol levels compared with patients treated with sita.
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, weekly exenatide reduced cholesterol more than sitagliptin.

    In plain wordsIn patients with diabetes, weekly exenatide reduced cholesterol more than sitagliptin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCholesterol
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with EQW also experienced significantly greater reductions in body weight and cholesterol levels compared with patients treated with sita.
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with diabetes, nausea was more frequent with weekly exenatide than sitagliptin and decreased over time.

    In plain wordsIn patients with diabetes, nausea was more frequent with weekly exenatide than sitagliptin and decreased over time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea incidence
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidences of the most common adverse events of nausea and diarrhea were higher in the EQW group compared with the sita group, and incidences of these adverse events decreased over time.
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with diabetes, diarrhea was more frequent with weekly exenatide than sitagliptin and decreased over time.

    In plain wordsIn patients with diabetes, diarrhea was more frequent with weekly exenatide than sitagliptin and decreased over time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiarrhea incidence
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidences of the most common adverse events of nausea and diarrhea were higher in the EQW group compared with the sita group, and incidences of these adverse events decreased over time.
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with diabetes, minor hypoglycemic events had low incidence with both weekly exenatide and sitagliptin.

    In plain wordsIn patients with diabetes, minor low blood sugar events were uncommon with both weekly exenatide and sitagliptin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedMinor hypoglycemic events
    Study

    n = 737

    Comparator
    Sitagliptin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both groups experienced a low incidence of minor hypoglycemic events.
    2 context sentences
    Summary · context
    Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, double-blind, comparator-controlled clinical trials were pooled and analyzed.
    Summary · context
    Analysis included 737 patients on background therapies of diet and exercise and/or metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00676338

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

AstraZenecan = 820Nov 2008 to Jan 2011

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 9 Apr 2015
CompletedPhase 3Results postedNCT00637273

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

AstraZenecan = 514Jan 2008 to Jul 2009

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.